|drug442||Biological Sample Collection Wiki||0.58|
|drug2998||Saliva collection Wiki||0.24|
|D004700||Endocrine System Diseases NIH||0.41|
|D011251||Pregnancy Complications, Infectious NIH||0.33|
There are 3 clinical trials
Since March 2020, SARS-CoV2 virus (nCoV19; COVID-19) is considered pandemic. Its high rate of spread and infection in the human population and the lack of effective and validated treatment have led the authorities of several countries to confine their populations to slow the spread of COVID-19. As part of the management of this health crisis, the screening of individuals is essential in order to isolate "infected cases". These screening tests are currently performed on nasopharyngeal swabs using RT-PCR for the detection of viral RNA. Although sensitive and specific, these tests remain relatively long (2-5 hours), expensive and the strong international demand for nucleic extraction kits and enzymes are factors limiting the implementation of widespread screening (problem of supply of swabs, molecular biology consumables). In order to prevent the risks of a shortage of screening means, we propose to develop an innovative alternative strategy, PCR-free, based on the detection of specific protein signatures in human saliva by MALDI-TOF MS profiling. MALDI-TOF MS profiling is a method used in routine diagnostics by microbiology laboratories for the identification of microorganisms. MALDI-TOF MS profiling has been successfully used to classify individuals according to their infectious status (oral pathologies) based on the analysis of their saliva, but also as a tool for the identification of respiratory viruses from cell culture supernatants. In addition, we have expertise and skills in the field of MALDI-TOF MS profiling and have implemented new strategies to improve the quality of profiles and their analysis, particularly in the context of entomological and vector identification projects. Finally, recent Chinese studies have reported that COVID-19 was detectable in saliva by RT-PCR. The main objective of this study is to develop a test based on the MALDI-TOF profiling method to detect individuals infected with SARS-CoV2 from saliva sample.
Description: The development of this test is based on machine learning techniques, which involve "training" a mathematical model, in which the results of the mass spectrometry analysis of saliva samples and clinical data will be used to determine the information needed to distinguish a saliva sample from a SARS-CoV2-infected participant from a healthy saliva sample.Measure: Development of a test based on the MALDI-TOF profiling method to detect individuals infected with SARS-CoV2 from saliva sample. Time: Day 30
Description: For each saliva sample, the status ("correct" or "incorrect") of the classification of the sample ("infected" or "not infected") by the test (MALDI-TOF MS profiling) will be determined. Then the rate of correct classification will be calculated. The test will be considered efficient when it has reached a correct classification rate of more than 95%.Measure: Rate of correct classification by the test (MALDI-TOF MS profiling) from saliva sample Time: Day 30
Description: For each saliva sample, the status ("correct" or "incorrect") of the classification of the sample ("infected" or "not infected") by RT-PCR will be determined. Then the rate of correct classification by RT-PCR will be calculated.Measure: Rate of correct classification by RT-PCR from saliva sample Time: Day 30
Description: On each saliva sample, the expression of proteins will be determined using mass spectrometry. By comparison between SARS-CoV2 infected saliva samples and non-infected saliva samples, the presence of proteins that are specifically expressed in SARS-CoV2 infected saliva samples will be determined.Measure: Identification of proteins specific to the SARS-CoV2 infection Time: Day 30
Description: On each SARS-CoV2 infected saliva sample, the presence of anti-SARS-CoV2 antibodies, by RT-PCR, will be determined.Measure: Presence of a positive anti-SARS-CoV2 antibody response by RT-PCR Time: Day 30
Description: In SARS-CoV2 infected participants (Covid+ hospitalization group and Covid+ outpatient group), the presence of a correlation between the presence of proteins specific to the SARS-CoV2 infection and the clinical evolution of patients will be determined.Measure: Correlation between the identified protein markers and the clinical course of the participants. Time: Day 30
Complete blood count parameters are routinely evaluated cost-effective markers in diagnosis and clinical follow-up of infectious diseases.There is increasing number of studies to report the course of COVID-19 in pregnancy. The current study aimed to elucidate the changes in hematologic parameters in response to SARS-CoV-2 infection and whether there was an increase in adverse perinatal outcomes such as increased neonatal intensive care unit admission and lower APGAR scores in pregnancies with COVID-19.
Description: cell count per mm3.Measure: complete blood count parameters (including the number of lymphocytes, Leukocytes, monocytes, platelets and red blood cells). Time: first 1 hour of hospitalization.
Description: 1st and 5th minute newborn assessmentMeasure: APGAR score Time: 5 minutes
Description: centimetersMeasure: maternal and newborn length Time: 5 minutes
Description: kilogramsMeasure: maternal and newborn weight Time: 2 minutes
Description: Celsius degreeMeasure: body temperature Time: 2 minutes
Coronavirus Disease-19 (COVID-19) is a global pandemics which affects many organs and systems with a range of morbidities and high mortality rates. There are a number of studies revealed that COVID-19 may affect the testes and male genital tract which may in turn disrupt the gonadal functions.The current study aimed to evaluate the effect of COVID-19 on semen parameters and sex-related hormone levels.
Description: cell count percentageMeasure: Semen analyses parameters including sperm motility (total, progressive, non-progressive and immotile Time: first 1 hour
Description: cell count per milliliters of semen sample.Measure: Semen analyses parameters including sperm concentration Time: first 1 hour
Description: percentage of normal formsMeasure: Semen analyses parameters including sperm morphology Time: first 1 hour
Description: millilitersMeasure: Semen analyses parameters including semen volume Time: first 1 hour
Description: nanograms per deciliterMeasure: Sex-related hormone levels including testosterone Time: 20 minutes
Description: Units per literMeasure: Sex-related hormone levels including follicle stimulating hormone and luteinizing hormone Time: 20 minutes
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports